Skip to main content

Table 1 Characteristics of the 17 included studies. There were 9 crossover and 8 parallel studies. The isoflavones tablets introduced were mainly in aglycone form. The abbreviations were listed below table.

From: Effects of isoflavones (soy phyto-estrogens) on serum lipids: a meta-analysis of randomized controlled trials

Study

Treatment (Rx) †

Isoflavones content in Rx (mg/d) ‡

Control

Isoflavones content in control (mg/d)

No. of subjects

Lipid status §

Subject gender ||

Length of treatment (weeks)

*Calvert 1981 [7]

soy biscuits

NA

soy biscuits

0

10

H

male

4

Clifton-Bligh 2001(I) [8]

T

57

T

     

Clifton-Bligh 2001(II) [8]

T

85.5

 

28.5

46

B

female

26

Dewell 2002 [9]

T

150 G = 40; D = 50; glycosides = 60

placebo

0

36

H

female

24

Hale 2002 [10]

T

80 G = 40; D = 40

placebo

0

29

NS

post

2

Han 2002 [11]

soy protein capsule

100 G = 70; D = 18; glycitein = 12

soy protein capsule

0

78

N

peri

16

Hodgson 1998 [12]

T

55 G = 30; D = 1; B = 16; F = 8

placebo

0

59

N

male & female

8

Howes 2000 [13]

T

40 G = 1; D = 0.5; B = 26; F = 16

placebo

0

75

NS

post

5

Mackey 2000 [14]

ISP

65

ISP

< 4

49

H

post

12

*Merz-Demlow 2000(I) [15]

ISP

113–144

ISP

     

*Merz-Demlow 2000(II) [15]

ISP

55–74

 

9–11

13

N

female

3

*Nestel 1997 [16]

T

40–80 G= 22–43; D = 17–33; glycitein= 1–3

placebo

0

21

B

female

5

*Nestel 1999(I) [17]

T

80 G = 8; D = 7; B = 49; F = 16

placebo

     

*Nestel 1999(II) [17]

T

40 G = 4; D = 3.5; B = 24.5; F = 8

 

0

13

B

female

5

*Samman 1999 [18]

T

86 G = 8.6; D = 7.4; B = 51.4; F = 18.6

placebo

0

14

N

pre

16

*Sanders 2002 [19]

soy burger

56 G = 34.8; D = 21.2

soy burger

2

22

N

male & female

2

*Simons 2000 [20]

T

80

placebo

0

20

N

post

8

Squadrito 2002 [21]

T

54 G= 54

placebo

0

60

N

female

24

*Urban 2001 [22]

T

70 G = 42; D = 27

ISP

3

28

N

elderly men

6

*Wangen 2001(I) [23]

ISP

110–154

ISP

     

*Wangen 2001(II) [23]

ISP

54–76

 

6–8.2

18

NS

post

4

  1. * crossover design † 'T' = isoflavone tablet; 'ISP' = isolated soy protein ‡ 'G' = Genistein; 'D' = Daidzein; 'B' = Biochanin A; 'F' = Formononectin §'H' = hyperlipidemic subjects, 'N' = normolipidemic subjects; 'B' = both hyper- and normolipidemic subjects; 'NS' = not specified || 'pre' = premenopausal women; 'peri' = perimenopausal women; 'post' = postmenopausal women